TBCRC 008: Early Change in (18)F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer

Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neo-adjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Nucl Med
Главные авторы: Connolly, Roisin M., Leal, Jeffrey P., Goetz, Matthew P., Zhang, Zhe, Zhou, Xian C., Jacobs, Lisa K., Mhlanga, Joyce, Joo, H O, Carpenter, John, Storniolo, Anna Maria, Watkins, Stanley, Fetting, John H., Miller, Robert S., Sideras, Kostandinos, Jeter, Stacie C., Walsh, Bridget, Powers, Penny, Zorzi, Jane, Boughey, Judy C., Davidson, Nancy E., Carey, Lisa A., Wolff, Antonio C., Khouri, Nagi, Gabrielson, Edward, Wahl, Richard L., Stearns, Vered
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352313/
https://ncbi.nlm.nih.gov/pubmed/25476537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.114.144741
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы